There is a potential of a third vote now, we will not know whether that is happening, but maybe we can work it so we can tagteam the chairmanship. Senator blumenthal i think is back with us. I will make certain he and i can trade positions so we can both vote. If that happens. The committee is reconvened. Mr. Gilman, if you are available , you have about a minute and a half left. We heard your testimony to that last point and we would love to hear your concluding remarks. Can you hear me . Mr. Gilman . Can you hear me . Yes sir. Myi am going to pick up testimony from where i left off . Yes, sir. Ok. I was determined to make isolation gowns because we had the equipment to cut and sew them. I quickly got a sample from a local hospital, design my own pattern, research the materials the gowns were made up, and built a prototype. I sent it to yell new haven hospital, they evaluated it and awarded me an order. There was a surge demand. Hospitals needed more gowns than they could buy from the
Runs just under two hours. Good afternoon, everyone. Thank you for being with us, or being near us, at least in the technology since. I welcome all of you to todays hearing that weve entitled, examining the response to the covid19 pandemic. The subcommittee at the sound of the gavel will come to order. As the nation continues to fight the unprecedented Public Health crisis, americans worked to protect against further spread of the virus while trying to maintain a certain degree of normalcy, including maintaining a job and earning a paycheck. There is not a corner of the u. S. Economy that has not felt the impact of the pandemic todays discussion will talk about the harmful effects on the Manufacturing Sector. During this pandemic, many in the Manufacturing Community have adapted their operations to help provide products needed to prevent the spread of the virus. Distributionlesale company that pivoted to manufacturing face masks in response to a dire National Supply shortage, or a cart
David hawkings is the editor in chief. There are leadership elections. Explain how they go about the two parties electing their leaders and can we see any changes . We will see some so, they meet in caucuses, different causes. No surprise here. The things are happening a little bit differently this year because of the pandemic. The Democratic Caucus which is happening the first of the meetings is happening today. There is a virtual opportunity for members to stay home, stay in their districts and cast the votes in the upcoming leadership elections using a secure app that the democrats have come up with. We wont see any changes at the top. The republican leadership, kevin mccarthy, steve scalise, maybe, maybe not liz cheney, thats staying the same. Were not seeing any changes at the top there either. Remarkably long run of nancy pelosi as the leader and jim clyburn of South Carolina as number three, thats all continuing. Thats continuing for a into a 16th year. Its a remarkably long run
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So